Overview
The goal of this clinical trial is to evaluate the effect of ACE inhibitors and SGLT-2 inhibitors on:
- Proteinuria
- Renal survival indices
Description
This is a randomized, double blind study. Patients are randomized to receive oral ACE inhibitors or combined ACEI and SGLT-2inhibitrs once daily for12 weeks.
Eligibility
Inclusion Criteria:
- Age between 10 and 18 years old,
- Nephrotic resistant patients,
- No history of diabetes,
- Estimated GFR≥60ml/min/1.73m2, will be evaluated by Schwartz formula,
- Caregivers' acceptance to be enrolled in the study.
Exclusion Criteria:
- Uncontrolled urinary tract infection at screening,
- Blood pressure is less than 5th percentile of the same gender, age, height,
- At risk of dehydration or volume depletion,
- Evidence of liver disease: defined by serum levels of alanine transaminase or aspartate transaminase >2 times the upper limit of normal during screening,
- History of organ transplantation, cancer, liver disease,
- History of noncompliance to medical regimens or unwillingness to comply with the study protocol.